Complications and thromboembolic events associated with tamoxifen therapy in patients with breast cancer undergoing microvascular breast reconstruction: a systematic review and meta-analysis

• Published in: Breast cancer research and treatment 2017-05, Vol.163 (1), p.1-10
• Main Authors: Parikh, Rajiv P., Odom, Elizabeth B., Yu, Liyang, Colditz, Graham A., Myckatyn, Terence M.
• Format: Article
• Language: English
• Subjects: Analysis; Antineoplastic Agents, Hormonal - adverse effects; Antineoplastic Agents, Hormonal - therapeutic use; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - surgery; Breast reconstruction; Cancer patients; Cancer research; Cancer therapies; Care and treatment; Complications and side effects; Drug therapy; Female; Hormones; Humans; Mammaplasty; Medical research; Medicine; Medicine & Public Health; Observational Studies as Topic; Oncology; Plastic surgery; Postoperative Complications - chemically induced; Randomized Controlled Trials as Topic; Review; Risk factors; Surgical Flaps - blood supply; Surgical outcomes; Systematic review; Tamoxifen; Tamoxifen - adverse effects; Tamoxifen - therapeutic use; Thromboembolism; Thromboembolism - chemically induced; Treatment Outcome
• ISSN: 0167-6806; 1573-7217
• DOI: 10.1007/s10549-017-4146-3

Purpose Tamoxifen therapy is integral in the treatment of patients with hormone receptor-positive breast cancer. However, there is an association between tamoxifen and thromboembolic events. Flap and systemic thromboembolic events have devastating consequences in microvascular breast reconstruction. Currently, there are conflicting data on the association between tamoxifen therapy and thromboembolic complications for patients undergoing microvascular breast reconstruction. The objective of this study is to determine if perioperative tamoxifen therapy modifies the risk of complications and thromboembolic events for patients with breast cancer undergoing microvascular breast reconstruction. Methods A comprehensive literature search was performed across six databases from January 2003 to February 2016. Pooled estimates and relative risk (RR) were calculated using a random-effects model, confounding was examined with meta-regression, and risk of bias was evaluated. Primary outcomes were thrombotic flap complications and total flap loss. Study quality was assessed using Downs and Black criteria. Results Of 95 studies reviewed, 4 studies comprising 1700 patients and 2245 procedures were included for analysis. Compared to non-recipients, patients on tamoxifen were at increased risk of developing thrombotic flap complications (pooled RR 1.5; 95% CI 1.14–1.98) and total flap loss (pooled RR 3.35; 95% CI 0.95–11.91). There was no significant heterogeneity present in either outcome and no evidence of publication bias. Conclusions Perioperative tamoxifen therapy may increase the risk of thrombotic flap complications and flap loss for patients with breast cancer undergoing microvascular reconstruction. These findings further the ability of providers to make evidence-based recommendations in the perioperative management of patients with breast cancer.